Abstract:Introduction. Hepatitis C virus (HCV) is not currently included in the United Kingdom routine antenatal screening program, but the latest guidelines from the Centers for Disease Control and Prevention, American Association for the Study of Liver Diseases, and Infectious Diseases Society of America recommend HCV screening for all pregnant women during each pregnancy. The aim of this study was to collect qualitative data on the feasibility and acceptability of antenatal HCV screening in pregnant women at the time of routine antenatal screening at 12 weeks, to estimate patient knowledge about HCV and identify the prevalence of HCV infection in antenatal women. Methods. This was a pilot study targeting a single hospital‐based antenatal clinic in Birmingham, initially conducted for eight weeks with a further extension of the study period to enhance recruitment to meet the feasibility target of 500 patients. Data collected included demographic and epidemiological details. Pregnant women attending the antenatal unit were given information regarding HCV and antenatal screening for HCV prior to their initial antenatal visit. During the antenatal visit, research nurses provided further information about the study and HCV infection. Consent was obtained for taking part in the study and testing for HCV using blood samples taken at the same time as other routine antenatal screening blood tests. All women who agreed to participate in the study were asked to complete an acceptability and knowledge questionnaire. All women had HCV antibody testing as the primary screening assay. The test result was communicated in writing to the women and their general practitioner. Confirmatory positive antibody tests were followed up with quantitative HCV PCR and genotype analysis. The outcomes of testing were no evidence of HCV infection and evidence of past HCV infection or current HCV infection. Results. Five hundred and forty‐nine women were approached in the antenatal clinic; 30 women refused consent while 29 women were excluded from the study (blood tests not performed after consenting, age less than 18 years, and consent form lost). Four hundred and ninety women were included in the study. The median age of the study population was 29 years (range, 18–46). Knowledge about blood‐borne viruses was limited; 75% of women had some understanding about antenatal hepatitis B (HBV) and human immunodeficiency virus (HIV) testing. Previous awareness about hepatitis C was reported by 55%. Ninety‐one percent of women found the information they were given about hepatitis C helpful. Ninety‐six percent of the women included in this study found the counselling they received about HCV useful and felt that the delivery of this information was carried out in an acceptable manner. Once given information about HCV, 99% felt that universal screening for HCV should be implemented. HCV antibody was negative in 489 women. One patient with a positive HCV antibody (prevalence: 0.2%) had a negative HCV PCR. Conclusion. Routine antenatal screening for HCV is not currently recommended in the UK. Our study suggests that antenatal HCV screening would be both feasible and acceptable to most pregnant women attending antenatal clinics. Though the awareness of HCV was low, with appropriate counselling and communication, 99% of pregnant women were in favor of antenatal screening for HCV. Antenatal screening would identify HCV‐positive mothers and allow follow‐up of their infants so that any infected mothers and infants could be offered effective curative therapy and prevent the progression of liver disease. The inclusion of HCV antenatal screening would complete the blood‐borne virus profile and enhance the WHO target to eliminate HCV in the UK.

Hepatitis C infection screening and connection to care among postpartum patients and exposed infants in two community hospitals, 3-year follow-up — Oregon, 2019–2024

Pediatric Hepatitis C Screening by Maternal Hepatitis C Infection Status During Pregnancy

[A Survey of the Current Status of Research on the Diagnosis and Treatment of Hepatitis C Virus Antibody-Positive Pregnant Women].

Hepatitis C Exposure Diagnosis and Testing in Infants Born to Hepatitis C Virus-infected Mothers

Best practices for hepatitis C linkage to care in pregnant and postpartum women: perspectives from the Treatment In Pregnancy for Hepatitis C Community of Practice

Hepatitis C Prevalence and Birth Outcomes among Pregnant Women in the United States: A 2010–2020 Population Study

Hepatitis C and obstetrical morbidity in a substance use disorder clinic: a role for telemedicine?

Maternal neighbourhood‐level social determinants of health and their association with paediatric hepatitis C screening among children exposed to hepatitis C in pregnancy

Birth Outcomes Among People with Hepatitis C in Pregnancy — Three U.S. States, 2018–2021

Hepatitis C Virus Cascade of Care Among Perinatal Patients in Maine Diagnosed With Opioid Use Disorder, 2015–2020

Prevalence of hepatitis C among pregnant women in an Appalachian population

Overview of Hepatitis C in Pregnancy: Screening, Management and Treatment

Understanding current antenatal Hepatitis C testing and care in maternity services in England

Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation

Feasibility and Acceptability of Antenatal Hepatitis C Screening: A Pilot Study

A Composite Score for Predicting Vertical Transmission of Hepatitis C: A Multicenter Study

Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing

Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic

Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017)

Hepatitis B and C in pregnancy: a review and recommendations for care

Identifying missed opportunities for hepatitis C virus antenatal testing and diagnosis in England